How Do Clinicians Decide if Medical Cannabis is Appropriate in the UK?

If you have spent any time looking into medical cannabis in the UK, you have likely come across a dizzying array of forums, private clinic websites, and conflicting advice. After nine years in NHS admin, I know exactly what this feels like: you are trying to navigate a system that feels designed to keep you at arm's length.

Since November 2018, medical cannabis has been legally available in the UK via specialist prescription. However, there is a massive gap between "legal" and "accessible." Understanding how a clinician actually makes that decision is the key to managing your expectations and avoiding the "salesy" jargon that tends to clutter this space.

Policy Takeaway: Just because a treatment is legal, it does not mean it is a standard or default option for any condition; it remains a tightly regulated, evidence-based intervention that sits outside of standard primary care pathways.

The Myth of the "Fixed List"

I hear this question every single day: "Is my condition on the list?"

I am going to be blunt because I value your time: there is no official, government-issued "fixed list" of conditions that guarantee a prescription for medical cannabis.

When you see clinics advertising a list of "eligible conditions," what they are actually sharing is a list of areas where they have previously identified clinical literature or evidence to support their prescribing. A clinician does not look at a list to see if you qualify; they look at you. They look at your specific diagnosis, the progression of your illness, your side-effect profile from previous medications, and your current quality of life.

Policy Takeaway: Eligibility is determined by individual clinical judgement, not by matching your condition to a pre-approved menu of ailments.

The Specialist Clinician Assessment: What Really Happens

In the UK, only doctors on the Specialist Register of the General Medical Council (GMC) can prescribe unlicensed cannabis-based products for medicinal use (CBPMs). You cannot get these from your GP. This is a critical distinction.

When you book a specialist evaluation for a cannabis prescription, the doctor isn't just looking to see if you have a diagnosis. They are conducting a risk-benefit analysis. They will look at your patient history assessment for cannabis eligibility with a fine-toothed comb. They want to know:

    What conventional medicines have you already tried? How did those medicines affect your symptoms? Did you experience significant side effects that made you stop them? Are there any contraindications, such as a history of psychosis or active heart disease, that make cannabis risky for you?

The goal is to determine if your condition is "treatment-resistant." If you walk into that appointment having never tried a standard pharmaceutical treatment, the specialist will almost certainly advise you to go back to your GP or consultant to exhaust those first-line options before cannabis is even considered.

The "Last Resort" Framing and the 2-Treatment Rule

You will hear the phrase "last resort" constantly. In clinical terms, this usually means that you have already attempted at least two conventional treatments, medications, or therapies relevant to your condition, and they have either failed to provide adequate relief or caused intolerable side effects.

Why is this standard? Because medical cannabis is currently classified as an "unlicensed" medication. In the UK, clinicians are professionally and legally responsible for proving that an unlicensed medicine is necessary and that licensed alternatives have been fully explored first. It is not about gatekeeping for the sake of it; it is about the clinical governance frameworks that keep doctors' licenses safe and patients protected.

The Two-Treatment Benchmark

Factor Clinical Consideration Treatment History Have 2+ licensed medications been tried? Evidence Is there data suggesting cannabis might help? Safety Are there risks like cardiac issues or mental health history? Monitoring Can you commit to follow-up appointments?

How NICE Guidance Shapes the Conversation

The National Institute for Health and Care Excellence (NICE) provides the "evidence-based recommendations" that form the bedrock of UK medical practice. NICE has published specific guidelines on cannabis-based medicinal products, and they are—to put it mildly—very conservative.

Because the clinical trials for cannabis are still maturing, NICE guidance is quite narrow. They specifically recommend against its use for many conditions because they believe the current evidence is not yet robust enough to justify widespread NHS funding.

However, private specialists are allowed to use their own clinical judgement for cannabis in the UK to prescribe outside of NICE guidelines, provided they have a strong rationale and documented evidence. This is why private clinics can sometimes offer options that an NHS trust would decline. But remember: just because they can prescribe it, doesn't mean they will if they aren't convinced it is the right clinical decision for your specific case.

Decoding the "Confusing Phrases" List

In my time as an admin, I’ve kept a running list of phrases that confuse patients. If you hear these during your consultation, here is what they actually mean in plain English:

image

    "Specialist Oversight": This means you aren't just getting a bottle of medication; you are committing to a structured program of follow-up appointments where the doctor monitors your reaction and adjusts the dosage. "Last Resort": We have tried the standard pharmaceutical pathways, they haven't worked or were too toxic, and we are now exploring unconventional options. "Evidence-Based Recommendation": The doctor is looking at scientific literature (not just anecdotal forum posts) to justify why they believe this product will help your specific condition. "Clinical Discretion": The doctor is taking personal responsibility for your prescription; they are deciding that the benefits outweigh the risks despite the lack of broad, gold-standard clinical trials.

What Should You Bring to Your Appointment?

If you are serious about pursuing this route, stop relying on memory. You need documentation. My biggest piece of advice is to request a "Summary Care Record" or a full printout of your medical history from your GP surgery.

Bring evidence of:

Your formal diagnosis from a specialist (not just a GP note). A list of all medications you have taken for this condition, including doses and the duration of use. Notes on why previous treatments stopped (e.g., "dizziness," "nausea," "no improvement").

When you have this prepared, the specialist evaluation for a cannabis prescription becomes a much more productive conversation. The doctor doesn't have to chase your records, and you demonstrate that you are a well-informed patient who has already done the "legwork" of trying standard care.

A Final Note of Caution

flixbaba.org

I have seen the industry shift rapidly over the last few years. There is a lot of noise out there. Avoid clinics that promise a "guaranteed outcome" or that suggest cannabis is a miracle cure-all. A good clinician will be honest about the fact that it is a trial-and-error process, that it might not work for everyone, and that it carries risks just like any other medication.

If a clinic seems like it is selling you a subscription rather than a healthcare service, walk away. Your health is not a product. It is a complex journey, and you deserve a clinician who views your medical cannabis request with the same level of caution and rigor as they would any other treatment option.

Policy Takeaway: Always prioritize clinics that emphasize long-term monitoring and detailed medical history reviews; if they are too quick to sign you up, they are moving too fast for your safety.

image

Disclaimer: I am an experienced healthcare administrator and writer, not a doctor. This information is for educational purposes only and does not constitute medical advice. Always speak with your GP or a qualified medical specialist regarding your personal health circumstances.